CRISPR Therapeutics
Manufacturing · Switzerland · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Baarerstrasse 14, Zug, Zug, 6300, Switze...Phone Number
+41 415613277Website
www.crisprtx.comRevenue
<$5 MillionStock Symbol
CRSPIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About CRISPR Therapeutics
Crispr Therapeutics, founded in 2013 and headquartered in Zug, Switzerland, is a developer of gene-based medications that target diseases at the molecular level.Explore more
CRISPR Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CRISPR Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if CRISPR Therapeutics had a recent Job posting/layoffs
CRISPR Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at CRISPR Therapeutics
Product Launch: Get notified when CRISPR Therapeutics launches new products
Check out if CRISPR Therapeutics is spiking on competitors!
Earning: See what the market has to say on CRISPR Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once CRISPR Therapeutics has new funding data
Check if CRISPR Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined CRISPR Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
CRISPR Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CRISPR Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CRISPR Therapeutics.
CRISPR Therapeutics financials insights
Gather financial insights about CRISPR Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Stock Offering
$56M
CRISPR Therapeutics Tech Stack
A closer look at the technologies used by CRISPR Therapeutics
See more technologies
Most Recent Scoops
Open Position
Project
CRISPR Therapeutics is advancing CTX611, a long-acting siRNA administered once every six months that targets factor XI as a blood thinner with reduced bleeding risk, with encouraging Phase 1 data reported and Phase 2 data in a total knee arthroplasty setting expected by end of this year. The program is expected to be Phase 3-ready by end of year or early next year.
Project
CRISPR Therapeutics has identified severe hypertriglyceridemia as the most likely Phase 3 indication for CTX310, citing limited existing treatment options and the appeal of a one-and-done therapy, with Phase 3 design to be informed by Phase 1B data and regulatory feedback expected by end of year.
Project
CRISPR Therapeutics has an ongoing Phase 2 total knee arthroplasty study for CTX611 enrolling more than 400 patients globally, with enrollment progressing well and top-line data expected by end of this year.
Project
CRISPR Therapeutics News & Media
3 Reasons to Buy CRISPR Therapeutics Stock
The company's innovative qualities may pay rich dividends down the road.Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now
There's more to young biopharma companies than their numbers, but those numbers are still an important part of each investment thesis.CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.CRISPR Therapeutics (CRSP) Is Up 11.3% After Broad Russell Growth Index Inclusion Has The Bull Case Changed?
In late June 2026, CRISPR Therapeutics AG was added to several Russell growth indexes, including the Russell 2000 Growth, 2500 Growth, 3000 Growth, 3000E Growth, and Small Cap Comp Growth benchmarks. This broad index inclusion increases the company’s visibility to benchmarked funds and could meaningfully influence how investors view its role in growth-oriented portfolios. We’ll now examine how this broad Russell growth index inclusion shapes CRISPR Therapeutics’ investment narrative and...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CRISPR Therapeutics
Sign Up For FreeTo access detailed company insights
Crispr Therapeutics, founded in 2013 and headquartered in Zug, Switzerland, is a developer of gene-based medications that target diseases at the molecular level.... Read More
